IN8bio, Inc. (INAB)
NASDAQ: INAB · Real-Time Price · USD
1.100
+0.090 (8.91%)
Sep 17, 2026, 10:39 AM EDT - Market open
IN8bio Employees
IN8bio had 18 employees as of June 30, 2026. The number of employees did not change compared to the same quarter last year.
Employees
18
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,037,056
Market Cap
10.84M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 18 | 0 | - |
| Mar 31, 2026 | 18 | 0 | - |
| Dec 31, 2025 | 17 | -1 | -5.56% |
| Sep 30, 2025 | 17 | -1 | -5.56% |
| Jun 30, 2025 | 18 | -21 | -53.85% |
| Mar 31, 2025 | 18 | -16 | -47.06% |
| Dec 31, 2024 | 18 | -13 | -41.94% |
| Sep 30, 2024 | 18 | -13 | -41.94% |
| Jun 30, 2024 | 39 | 10 | 34.48% |
| Mar 31, 2024 | 34 | 6 | 21.43% |
| Dec 31, 2023 | 31 | 5 | 19.23% |
| Sep 30, 2023 | 31 | 5 | 19.23% |
| Jun 30, 2023 | 29 | 8 | 38.10% |
| Mar 31, 2023 | 28 | 7 | 33.33% |
| Dec 31, 2022 | 26 | 7 | 36.84% |
| Sep 30, 2022 | 26 | 13 | 100.00% |
| Jun 30, 2022 | 21 | 7 | 50.00% |
| Mar 31, 2022 | 21 | 7 | 50.00% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| CytoMed Therapeutics | 42 |
| Vistagen Therapeutics | 41 |
| Senti Biosciences Holdings | 39 |
| Lunai Bioworks | 29 |
| Theriva Biologics | 16 |
| FibroBiologics | 15 |
| Azitra | 13 |
| Purple Biotech | 10 |
INAB News
- 3 days ago - IN8bio Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 3 days ago - IN8bio Slides: Corporate presentation - Filings
- 7 days ago - IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewsWire
- 8 days ago - IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development - GlobeNewsWire
- 5 weeks ago - IN8bio reports Q2 EPS (25c), consensus (37c) - TheFly
- 6 weeks ago - IN8bio Quarterly report: Q2 2026 - Filings
- 6 weeks ago - IN8bio Earnings release: Q2 2026 - Filings
- 2 months ago - IN8bio therapy doubles progression free survival in brain cancer trial - TheFly